Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Convatec appoints Jens Viebke as Non-Executive Director

Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration Committee...

Champion Health uses physiotherapist review to strengthen digital MSK triage

Champion Health's Nexa puts a registered physiotherapist into every MSK treatment decision, aiming to reduce delays, improve treatment suitability and make absence outcomes easier to measure...

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis, showing lung concentrations in a therapeutic range, target pathway engagement and..

Cizzle Bio expands the clinical pathway for CIZ1B Lung Cancer testing

Cizzle Bio has established a provider ordering and onboarding pathway for its CIZ1B lung cancer blood test in Dallas-Fort Worth and San Antonio, creating a structured route for clinical adoption...

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients...

Oxford Nanopore appoints David Miller as Chief Development and Product Officer

Oxford Nanopore Technologies has appointed David Miller as Chief Development and Product Officer and confirmed Conor McKechnie as Chief Marketing and Communications Officer. The new executive hires, both joining the..

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026...

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons...

Physitrack reports 8% revenue growth and profitable Q2 2026

Physitrack reported Q2 2026 revenue of €3.4 million, up 8% year on year, with adjusted EBITDA of €1.2 million and a 34% margin. The company highlighted continued Lifecare growth, the..

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers...

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer...

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory...

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions...

Spire Healthcare updates interim results release date

Spire Healthcare has delayed the expected release of its interim results for the six months ended 30 June 2026 to 30 September 2026...

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...

EDX Medical targets corporate health market with new screening service

EDX Medical is preparing to launch a corporate health screening service covering 14,000 employees, with testing expected to begin in Q4 2026...

BIOG keeps its focus on small-cap biotech and M&A potential

BIOG remains focused on small-cap biotech and potential takeover targets, with its managers still seeing value across the portfolio...

Smith & Nephew CFO John Rogers to step down in September

Smith & Nephew has announced John Rogers will leave as chief financial officer, with Pierre Palassian appointed interim CFO until a successor is named...

Oxford Nanopore lifts gross margin and improves EBITDA in H1 2026

Oxford Nanopore reported higher first-half revenue, improved gross margin and updated its 2030 revenue and EBITDA margin targets...

Nuformix reports positive NXP002 inhalation study results

Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning...
Search

Funds

Health

Convatec appoints Jens Viebke as Non-Executive Director

Convatec has appointed Dr Jens Viebke as a Non-Executive Director with immediate effect and added him to the Remuneration Committee...

Champion Health uses physiotherapist review to strengthen digital MSK triage

Champion Health's Nexa puts a registered physiotherapist into every MSK treatment decision, aiming to reduce delays, improve treatment suitability and make absence outcomes easier to measure...

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis, showing lung concentrations in a therapeutic range, target pathway engagement and evidence of a viable safety window. The company is now advancing target identification work, planning toxicology studies and continuing partnering discussions ahead of the European Respiratory Society Congress...

Cizzle Bio expands the clinical pathway for CIZ1B Lung Cancer testing

Cizzle Bio has established a provider ordering and onboarding pathway for its CIZ1B lung cancer blood test in Dallas-Fort Worth and San Antonio, creating a structured route for clinical adoption...

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients...

Oxford Nanopore appoints David Miller as Chief Development and Product Officer

Oxford Nanopore Technologies has appointed David Miller as Chief Development and Product Officer and confirmed Conor McKechnie as Chief Marketing and Communications Officer. The new executive hires, both joining the leadership team this autumn, are intended to align product development, marketing and commercial execution as the company scales its differentiated technology platform...

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026...

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons...

Physitrack reports 8% revenue growth and profitable Q2 2026

Physitrack reported Q2 2026 revenue of €3.4 million, up 8% year on year, with adjusted EBITDA of €1.2 million and a 34% margin. The company highlighted continued Lifecare growth, the US launch of its Remote Therapeutic Monitoring platform and further investment in North American expansion...

EDX Medical raises £2.7m to expand employee health screening service

EDX Medical has raised approximately £2.7m through a share subscription to support the expansion of its employee health screening service, as discussions progress with several major UK employers...

GSK gains priority FDA review for Jemperli in rectal cancer

GSK says the US FDA has accepted Jemperli for priority review in previously untreated stage II and III locally advanced rectal cancer...

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory...

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions...

Spire Healthcare updates interim results release date

Spire Healthcare has delayed the expected release of its interim results for the six months ended 30 June 2026 to 30 September 2026...

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners...

EDX Medical targets corporate health market with new screening service

EDX Medical is preparing to launch a corporate health screening service covering 14,000 employees, with testing expected to begin in Q4 2026...

BIOG keeps its focus on small-cap biotech and M&A potential

BIOG remains focused on small-cap biotech and potential takeover targets, with its managers still seeing value across the portfolio...

Smith & Nephew CFO John Rogers to step down in September

Smith & Nephew has announced John Rogers will leave as chief financial officer, with Pierre Palassian appointed interim CFO until a successor is named...

Oxford Nanopore lifts gross margin and improves EBITDA in H1 2026

Oxford Nanopore reported higher first-half revenue, improved gross margin and updated its 2030 revenue and EBITDA margin targets...

Nuformix reports positive NXP002 inhalation study results

Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning...
Search

Funds

Health

FTSE 100

Funds